Overview
Phibro Animal Health Corp saw insider sales totaling $1.1 million this week as director Jack Bendheim and BFI Co., LLC, a stake-holder owning ten percent of the company, reported the transactions. The trades took place between February 24 and February 26, 2026, and were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on May 30, 2025.
Sale details
The securities disposed of were Class A common stock of Phibro Animal Health (NASDAQ: PAHC). In total, 20,120 shares were sold at prices spanning $51.2679 to $54.2826. The breakdown by date and lot is as follows:
- February 24, 2026 - 5,889 shares sold at a weighted average price of $51.2679 (range $50.755 to $51.75), and a separate lot of 1,151 shares sold at a weighted average price of $51.8799 (range $51.80 to $52.065).
- February 25, 2026 - 7,040 shares sold at an average price of $51.7104 (range $51.275 to $52.27).
- February 26, 2026 - two lots: 6,329 shares at a weighted average price of $53.6690 (range $53.21 to $54.10), and 711 shares at a weighted average price of $54.2826 (range $54.27 to $54.355).
Following these transactions, BFI Co., LLC indirectly holds 1,480 shares of Phibro, and Jack Bendheim directly holds 16,840 shares.
Market context and valuation note
At the time of the reported sales the stock was trading close to its 52-week high of $56.30, with the most recent quote at $54.70. An InvestingPro analysis referenced in the report characterizes the share price as appearing overvalued at current levels, citing a price-to-earnings ratio of 24.15 and a Price/Book multiple of 6.48.
Recent company results
Phibro Animal Health’s fiscal second quarter of 2026 results were stronger than consensus expectations. The company recorded earnings per share of $0.87 versus the forecast of $0.68, representing a 27.94% earnings surprise. Revenue for the period totaled $373.9 million, exceeding the anticipated $355.24 million by 5.25%. The report notes that analyst firms have not been cited as issuing upgrades or downgrades in response to these results, and there are no reports of mergers or other significant company news at this time. The company’s recent earnings and revenue figures are presented as indicators of its current financial position.
Implications
The sale activity was executed under an established Rule 10b5-1 plan, indicating the trades were pre-arranged. The report does not attribute any further motives or implications to the transactions. It also does not report any follow-on corporate actions such as mergers, nor does it note any analyst rating changes tied to the company’s latest quarterly results.
Key points
- Director Jack Bendheim and BFI Co., LLC sold 20,120 shares of Phibro Animal Health between Feb. 24-26, 2026, totaling $1.1 million.
- Transactions were implemented under a Rule 10b5-1 trading plan adopted May 30, 2025; post-sale holdings are 16,840 shares (Bendheim directly) and 1,480 shares (BFI indirectly).
- Phibro reported a fiscal Q2 2026 EPS of $0.87 versus $0.68 expected and revenue of $373.9 million versus $355.24 million expected.
Risks and uncertainties
- Valuation concerns - InvestingPro analysis described the stock as appearing overvalued based on a P/E of 24.15 and a Price/Book of 6.48.
- Insider transactions - Significant insider sales, even when executed under a 10b5-1 plan, can create uncertainty for investors regarding near-term insider sentiment.
- Analyst coverage - The report notes no cited analyst upgrades or downgrades following earnings, leaving market reaction via formal coverage updates unclear.
Note: This article confines itself to the transactions and company disclosures reported; it does not offer investment advice or speculate beyond the stated facts.